Document Detail

Inhibitory effect of TCV-309, a novel platelet activating factor (PAF) antagonist, on endotoxin-induced disseminated intravascular coagulation in rats: possible role of PAF in tissue factor generation.
MedLine Citation:
PMID:  8332959     Owner:  NLM     Status:  MEDLINE    
The possible involvement of platelet activating factor (PAF) in the pathogenesis of endotoxin-induced disseminated intravascular coagulation (DIC) was investigated in rats using a novel potent PAF antagonist, TCV-309. TCV-309 (> 1 mg/kg, i.v.) showed beneficial effects in rats with experimental DIC induced by a 4-hour sustained infusion of endotoxin (1 mg/kg) in a dose-dependent manner. TCV-309 (1 mg/kg) significantly ameliorated the decrease in platelet count and plasma fibrinogen, the prolongation of prothrombin time (PT) and activated partial thromboplastin time (APTT) and the increase in fibrin and fibrinogen degradation products (FDP) and inhibited glomerular fibrin deposition. Furthermore, plasma tissue factor (TF) activity was greatly increased in the DIC rats, and this was also significantly decreased by TCV-309 (1 mg/kg). TCV-309 (1 mg/kg) did not affect these parameters in normal rats. A 4-hour sustained infusion of PAF (60 micrograms/kg) caused mild but significant changes in some DIC parameters such as PT, fibrinogen and FDP concentration and increased the plasma TF activity. TCV-309 (1 mg/kg) inhibited all these PAF-induced changes. TCV-309 (0.1 mM) itself had no direct in vitro effects on the blood coagulation system including TF activity. These results strongly suggest that PAF plays a role in the pathogenesis of endotoxin-induced DIC via the generation of TF. Prophylactic use of PAF antagonists may therefore be useful for the treatment of DIC with sepsis.
M Kawamura; Z Terashita; Y Imura; A Shino; K Nishikawa
Related Documents :
3007379 - Enalapril in congestive heart failure: acute and chronic invasive hemodynamic evaluation.
2066319 - Influence of growth rate and exposure to bulls on age at puberty in beef heifers.
8809379 - Cardiorespiratory effects of a 5ht2 antagonist (r51703) in awake and anesthetized dogs.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Thrombosis research     Volume:  70     ISSN:  0049-3848     ISO Abbreviation:  Thromb. Res.     Publication Date:  1993 May 
Date Detail:
Created Date:  1993-08-17     Completed Date:  1993-08-17     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0326377     Medline TA:  Thromb Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  281-93     Citation Subset:  IM    
Biology Research Laboratory, Takeda Chemical Industries, Ltd., Osaka, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Disease Models, Animal
Disseminated Intravascular Coagulation / chemically induced,  drug therapy*
Dose-Response Relationship, Drug
Drug Evaluation, Preclinical
Isoquinolines / pharmacology*,  therapeutic use
Platelet Activating Factor / antagonists & inhibitors,  physiology*
Pyridinium Compounds / pharmacology*,  therapeutic use
Rats, Sprague-Dawley
Thromboplastin / biosynthesis
Reg. No./Substance:
0/Isoquinolines; 0/Platelet Activating Factor; 0/Pyridinium Compounds; 0/Tetrahydroisoquinolines; 131311-25-6/TCV 309; 9035-58-9/Thromboplastin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  HIV infection and AIDS in Texas. A Special Report.
Next Document:  The direct binding of human factor VII in plasma to recombinant human tissue factor.